<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetologia</journal-id><journal-title-group><journal-title>Diabetologia</journal-title></journal-title-group><issn pub-type="ppub">0012-186X</issn><issn pub-type="epub">1432-0428</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19876613</article-id><article-id pub-id-type="pmc">2789932</article-id><article-id pub-id-type="publisher-id">1577</article-id><article-id pub-id-type="doi">10.1007/s00125-009-1577-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ritz</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Viberti</surname><given-names>G. C.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ruilope</surname><given-names>L. M.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rabelink</surname><given-names>A. J.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Izzo</surname><given-names>J. L.</given-names><suffix>Jr</suffix></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Katayama</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Ito</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Mimran</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Menne</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Rump</surname><given-names>L. C.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Januszewicz</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Haller</surname><given-names>H.</given-names></name><address><email>haller.hermann@mh-hannover.de</email></address><xref ref-type="aff" rid="Aff11">11</xref></contrib><aff id="Aff1"><label>1</label>Department of Nephrology, University of Heidelberg, Heidelberg, Germany </aff><aff id="Aff2"><label>2</label>KCL Guy&#x02019;s Hospital, London, UK </aff><aff id="Aff3"><label>3</label>Division of Hypertension, Hospital 12 de Octubre, Madrid, Spain </aff><aff id="Aff4"><label>4</label>Department of Nephrology and Hypertension, Leiden University Medical Center, Leiden, the Netherlands </aff><aff id="Aff5"><label>5</label>Department of Medicine, Erie County Medical Center, Buffalo, NY USA </aff><aff id="Aff6"><label>6</label>The Fourth Department of Medicine, Saitama Medical School, Saitama, Iruma, Japan </aff><aff id="Aff7"><label>7</label>Department of Clinical Medicine, Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan </aff><aff id="Aff8"><label>8</label>Hospital Lapeyronie, Montpellier, France </aff><aff id="Aff9"><label>9</label>Medical Clinic, Marienhospital Herne, University Clinic Ruhr-University-Bochum, Herne, Germany </aff><aff id="Aff10"><label>10</label>Department of Hypertension, Institute of Cardiology, Warsaw, Poland </aff><aff id="Aff11"><label>11</label>Department of Nephrology and Hypertension, Hanover Medical School, Carl-Neuberg Str. 1, 30625 Hannover, Germany </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>10</month><year>2009</year></pub-date><pub-date pub-type="pmc-release"><day>30</day><month>10</month><year>2009</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2010</year></pub-date><volume>53</volume><issue>1</issue><fpage>49</fpage><lpage>57</lpage><history><date date-type="received"><day>22</day><month>7</month><year>2009</year></date><date date-type="accepted"><day>10</day><month>8</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2009</copyright-statement></permissions><abstract><sec><title>Aims/hypothesis</title><p>In contrast to microalbuminuric type 2 diabetic patients, the factors correlated with urinary albumin excretion are less well known in normoalbuminuric patients. This may be important because even within the normoalbuminuric range, higher rates of albuminuria are known to be associated with higher renal and cardiovascular risk.</p></sec><sec><title>Methods</title><p>At the time of screening for the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Study, the urinary albumin/creatinine ratio (UACR) was 0.44&#x000a0;mg/mmol in 4,449 type 2 diabetic patients. The independent correlates of UACR were analysed.</p></sec><sec><title>Results</title><p>Independent correlates of UACR during baseline were (in descending order): night-time systolic BP (<italic>r</italic><sub>s</sub>&#x02009;=&#x02009;0.19); HbA<sub>1c</sub> (<italic>r</italic><sub>s</sub>&#x02009;=&#x02009;0.18); mean 24&#x000a0;h systolic BP (<italic>r</italic><sub>s</sub>&#x02009;=&#x02009;0.16); fasting blood glucose (<italic>r</italic><sub>s</sub>&#x02009;=&#x02009;0.16); night-time diastolic BP (<italic>r</italic><sub>s</sub>&#x02009;=&#x02009;0.12); office systolic BP, sitting (<italic>r</italic><sub>s</sub>&#x02009;=&#x02009;0.11), standing (<italic>r</italic><sub>s</sub>&#x02009;=&#x02009;0.10); estimated GFR (<italic>r</italic><sub>s</sub>&#x02009;=&#x02009;0.10); heart rate, sitting (<italic>r</italic><sub>s</sub>&#x02009;=&#x02009;0.10); haemoglobin (<italic>r</italic><sub>s</sub>&#x02009;=&#x02009;&#x02212;0.10); triacylglycerol (<italic>r</italic><sub>s</sub>&#x02009;=&#x02009;0.09); and uric acid (<italic>r</italic><sub>s</sub>&#x02009;=&#x02009;&#x02212;0.08; all <italic>p</italic>&#x02009;&#x02264;&#x02009;0.001). Significantly higher albumin excretion rates were found for the following categorical variables: higher waist circumference (more marked in men); presence of the metabolic syndrome; smoking (difference more marked in males); female sex; antihypertensive treatment; use of amlodipine; insulin treatment; family history of diabetes; and family history of cardiovascular disease (more marked in women).</p></sec><sec><title>Conclusions/interpretation</title><p>Although observational correlations do not prove causality, in normoalbuminuric type 2 diabetic patients the albumin excretion rate is correlated with many factors that are potentially susceptible to intervention.</p></sec><sec><title>Trial registration:</title><p>ClinicalTrials.gov ID no.: NCT00185159</p></sec><sec><title>Funding:</title><p>This study was sponsored by Daichii-Sankyo.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Albuminuria</kwd><kwd>Diabetes</kwd><kwd>Diabetic nephropathy</kwd><kwd>Epidemiology</kwd><kwd>Hypertension</kwd><kwd>Proteinuria</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2010</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>In both diabetic and non-diabetic patients, albuminuria has been recognised as an important renal and cardiovascular risk factor [<xref ref-type="bibr" rid="CR1">1</xref>]. Although, using chemical methods, albuminuria had been detected in patients without primary renal disease more than 100&#x000a0;years ago [<xref ref-type="bibr" rid="CR2">2</xref>], it was only after the introduction of immune detection methods [<xref ref-type="bibr" rid="CR3">3</xref>] and the recognition that albuminuria is a predictor of diabetic nephropathy in type 1 and type 2 diabetes [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>] that there was an explosive growth of information in this field.</p><p>The issue whether there is a safe threshold value of albuminuria has recently provoked intense discussion, mainly because in both non-diabetic [<xref ref-type="bibr" rid="CR6">6</xref>] and diabetic [<xref ref-type="bibr" rid="CR7">7</xref>] patients, urinary albumin concentrations in the upper normal range have been found to predict both cardiovascular [<xref ref-type="bibr" rid="CR6">6</xref>] and renal plus cardiovascular events [<xref ref-type="bibr" rid="CR7">7</xref>] in high risk [<xref ref-type="bibr" rid="CR6">6</xref>] and low risk [<xref ref-type="bibr" rid="CR8">8</xref>] populations. For these and other reasons it has been proposed by some authors to abandon microalbuminuria as a diagnostic category and to treat urinary albumin excretion (UAE) as a continuous variable, much like BP or serum cholesterol concentration [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>A great number of past and recent studies have evaluated the evolution of UAE from normoalbuminuria to microalbuminuria and its correlates in adolescent [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>] and adult [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>] type 1 diabetic patients. Information on type 2 diabetic patients is scarcer and is available only for some small cohorts [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p>The ROADMAP (Randomised Olmesartan and Diabetes Microalbuminuria Prevention) Study [<xref ref-type="bibr" rid="CR16">16</xref>] started in 2004 and provided a unique opportunity to investigate the factors which correlate with albumin excretion rates across the range of normoalbuminuric values in a large cohort of type 2 diabetic patients. Knowledge of these factors is of interest because albuminuria is correlated with cardiovascular and renal risk. It is the goal of the ROADMAP Study to provide further information on the selection of strategies for primary prevention of diabetic nephropathy.</p><p>In normoalbuminuric type 2 diabetic patients, it has already been shown that an ACE inhibitor reduces the risk of de novo onset of microalbuminuria [<xref ref-type="bibr" rid="CR17">17</xref>], but, as recently emphasised in a Cochrane review [<xref ref-type="bibr" rid="CR18">18</xref>], there is a deficit of information on angiotensin receptor blockers (ARBs). The aim of the ROADMAP study is to provide evidence of whether or not it is possible to prevent the development of microalbuminuria by administration of the ARB olmesartan medoxomil.</p><p>In the present study, we analysed the baseline albuminuria levels in the ROADMAP cohort and determined which factors correlate with the degree of albuminuria within the so-called normoalbuminuric range.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><p>The design of the ROADMAP Study has been described in detail previously [<xref ref-type="bibr" rid="CR16">16</xref>]. In the following details relating to the baseline data will be briefly summarised.</p><p><bold>Study design and organisation</bold> ROADMAP is a randomised, double-blind, placebo-controlled, parallel-group, multicentre phase 3 study that is being conducted in 262 collaborating centres in 19 European countries. The study protocol, which complies with the principles of Good Clinical Practice and the Declaration of Helsinki, has been approved by the relevant ethics committee at each participating centre. Written informed consent was required from each patient before enrolment in the trial.</p><p><bold>Study population</bold> The study has recruited 4,449 white patients (2,054 male and 2,395 female; age range, 18&#x02013;75&#x000a0;years) with: type 2 diabetes (fasting plasma glucose &#x02265;7.0&#x000a0;mmol/l and HbA<sub>1c</sub> &#x02265; 6.5%, or treatment for diabetes); normoalbuminuria (&#x02264;35&#x000a0;mg [women] or &#x02264;25&#x000a0;mg [men] albumin/g urinary creatinine); and at least one additional cardiovascular risk factor, including a lipid disorder defined as &#x0003e;5.2&#x000a0;mmol/l cholesterol or statin treatment, HDL-cholesterol &#x0003c;1.04&#x000a0;mmol/l, triacylglycerol &#x0003e;1.70&#x000a0;mmol/l, high systolic BP (SBP) (&#x02265;130&#x000a0;mmHg) and diastolic BP (DBP) (&#x02265;80&#x000a0;mmHg) or antihypertensive medication, obesity (BMI&#x02009;&#x02265;&#x02009;28&#x000a0;m<sup>2</sup>/kg), high waist circumference (&#x0003e;102&#x000a0;cm [men], &#x0003e;88&#x000a0;cm [women]) or smoking more than five cigarettes per day.Exclusion criteria included documented renal and/or renal&#x02013;vascular disease, estimated GFR (eGFR) &#x0003c;60&#x000a0;ml&#x000a0;min<sup>&#x02212;1</sup>&#x000a0;m<sup>&#x02212;2</sup>, recent cardiovascular event, severe hypertension (SBP&#x02009;&#x0003e;&#x02009;200&#x000a0;mmHg and/or DBP&#x02009;&#x0003e;&#x02009;110&#x000a0;mmHg) and recent (&#x0003c;26&#x000a0;weeks) treatment with ARBs or ACE inhibitors. Patient recruitment commenced in 2004 and was completed in the first half of 2006.Office BP measurements were performed between 06:00 and 11:00&#x000a0;hours as trough readings and made three times in the sitting position (with mean calculated) and once standing, using standardised oscillometric OMRON HEM-907 BP monitors (Omron, Stuttgart, Germany).In 1,234 patients, 24&#x000a0;h ambulatory BP monitoring (ABPM) was performed at baseline visit, using BOSO TM-2430 ambulatory BP measurement devices (Boso, Jungingen, Germany). BP was recorded for a 24&#x000a0;h period. During the day (07:00&#x02013;22:00&#x000a0;hours) measurements were performed every 15&#x000a0;min and during the night (22:00&#x02013;07:00&#x000a0;hours) every 30&#x000a0;min.The urinary albumin/creatinine ratio (UACR) and all other laboratory values were determined in a central laboratory (CRL-Medinet, Breda, the Netherlands) within 24&#x000a0;h after obtaining the urine and blood samples from the patient. Urinary albumin was measured using immunoturbidimetry (Roche, Basel, Switzerland).In a screening visit the potential eligibility for the study was established by determining the UACR by morning spot urine testing. After a pre-randomisation phase (maximum duration 4&#x000a0;weeks) during which normoalbuminuria was confirmed by two additional independent morning spot urine tests. For the analysis of baseline values the average of three UACR spot urine samples was used.</p><p><bold>Statistical analysis</bold> Baseline characteristics were analysed by the following descriptive statistics: for dichotomous and categorical variables absolute and relative frequencies (counts and percents) were calculated, whereby the denominator for per cents is defined as the number of patients with non-missing values.Comprehensive data summaries were performed by means of sample characteristics for all continuous variables (<italic>n</italic>; missing <italic>n</italic>; arithmetic mean; SD; minimum, lower quartile, median, upper quartile, maximum and geometric mean if appropriate).Correlations with albuminuria at screening were calculated for continuous variables by means of Spearman rank correlation coefficients (univariate and multivariate analysis; multivariate regression model with stepwise selection for log<sub><italic>e</italic></sub> albumin/creatinine ratio) and for categorical variables by means of a Wilcoxon rank sums test (two-sided test, normal approximation of test statistics of this non-parametric test).
<disp-formula id="Equ1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ {\text{eGFR}}\left( {{\text{ml}}\;{\text{mi}}{{\text{n}}^{ - {\text{1}}}}{\text{1}}.{\text{73}}\;{{\text{m}}^{ - {\text{2}}}}} \right) = {\text{16442}} \times {\left( {\text{PCr}} \right)^{ - {\text{1}}.{\text{154}}}} \times {\left( {{\text{age}}\;{\text{in}}\;{\text{years}}} \right)^{ - 0.{\text{2}}0{\text{3}}}}\left( { \times 0.{\text{742}}\;{\text{for}}\;{\text{female}}\;{\text{patients}}} \right), $$\end{document}</tex-math><graphic xlink:href="125_2009_1577_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula>where PCr is serum creatinine measured in micromole per litre.</p></sec><sec id="Sec3"><title>Results</title><p><bold>Patient data at baseline</bold> The baseline data are summarised in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. A total of 4,449 type 2 diabetic patients were included in the study: 90.3% of the patients had hypertension, defined as a BP&#x02009;&#x0003e;&#x02009;130/80&#x000a0;mmHg or antihypertensive treatment; 67.5% of patients were receiving antihypertensive treatment; 71.6% had lipid disorders. A high percentage of the patients were overweight and had central obesity.
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Patient data at baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>Total</th></tr></thead><tbody><tr><td>Total</td><td>4,449</td></tr><tr><td>Women, <italic>n</italic> (%)</td><td>2,395 (53.8)</td></tr><tr><td>Age (years)</td><td>57.7&#x02009;&#x000b1;&#x02009;8.7 (58)</td></tr><tr><td>Known duration of diabetes (years)</td><td>6.1&#x02009;&#x000b1;&#x02009;6.0 (4.3)</td></tr><tr><td>Insulin treatment, <italic>n</italic> (%)</td><td>821 (18.5%)</td></tr><tr><td>Oral hypoglycaemic agents</td><td>3,752 (84.3)</td></tr><tr><td>HbA<sub>1c</sub> (%)</td><td>7.6&#x02009;&#x000b1;&#x02009;1.6 (7.3)</td></tr><tr><td>Fasting blood glucose (mmol/l)</td><td>9.1&#x02009;&#x000b1;&#x02009;3.1 (8.4)</td></tr><tr><td>SBP (mmHg)</td><td>140.8&#x02009;&#x000b1;&#x02009;16.3 (140.0)</td></tr><tr><td>DBP (mmHg)</td><td>84.0&#x02009;&#x000b1;&#x02009;9.8 (84.0)</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>31.0&#x02009;&#x000b1;&#x02009;4.9 (30.5)</td></tr><tr><td>Central obesity, <italic>n</italic> (%)<sup>a</sup></td><td>3,181 (71.5)</td></tr><tr><td>Metabolic syndrome, <italic>n</italic> (%)<sup>b</sup></td><td>3,528 (79.3)</td></tr><tr><td>Current smokers, <italic>n</italic> (%)<sup>c</sup></td><td>831 (18.7)</td></tr><tr><td>eGFR (ml&#x000a0;min<sup>&#x02212;1</sup> 1.73&#x000a0;m<sup>&#x02212;2</sup>)</td><td>84.5&#x02009;&#x000b1;&#x02009;16.8 (83.8)</td></tr><tr><td>Haemoglobin (g/l)</td><td>142&#x02009;&#x000b1;&#x02009;13 (141)</td></tr><tr><td>Triacylglycerol (mmol/l)</td><td>2.1&#x02009;&#x000b1;&#x02009;1.3 (1.8)</td></tr><tr><td>Total cholesterol (mmol/l)</td><td>5.3&#x02009;&#x000b1;&#x02009;1.1 (5.2)</td></tr><tr><td>LDL-cholesterol (mmol/l)</td><td>3.2&#x02009;&#x000b1;&#x02009;0.9 (3.1)</td></tr><tr><td>HDL-cholesterol (mmol/l)</td><td>1.2&#x02009;&#x000b1;&#x02009;0.3 (1.2)</td></tr><tr><td>Uric acid (&#x000b5;mol/l)</td><td>321&#x02009;&#x000b1;&#x02009;83 (321)</td></tr><tr><td>Known family history of diabetes, <italic>n</italic> (%)</td><td>2,194 (49.3)</td></tr><tr><td>Known family history of CV events, <italic>n</italic> (%)</td><td>1,678 (37.7)</td></tr></tbody></table><table-wrap-foot><p>Values are means&#x000b1;SD (median) for continuous variables, or <italic>n</italic> (%) for categorical variables</p><p><sup>a</sup>High waist circumference: &#x0003e;102&#x000a0;cm in men, &#x0003e;88&#x000a0;cm in women</p><p><sup>b</sup>NCEP ATP III criteria</p><p><sup>c</sup>More than five cigarettes per day</p><p>CV, cardiovascular</p></table-wrap-foot></table-wrap></p><p><bold>Albuminuria at screening</bold> In these patients the albumin/creatinine ratio in morning spot urine tests was log<sub><italic>e</italic></sub> normally distributed with a median of 0.44&#x000a0;mg/mmol creatinine (interquartile range 0.28&#x02013;0.81; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). In men, the median was 0.41&#x000a0;mg/mmol creatinine (interquartile range 0.24&#x02013;0.75, mean 0.58&#x02009;&#x000b1;&#x02009;0.78, geometric mean 0.43) and in women the median was 0.46&#x000a0;mg/mmol creatinine (interquartile range 0.31&#x02013;0.88, mean 0.67&#x02009;&#x000b1;&#x02009;0.54, geometric mean 0.52).
<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Relationship of UACR with quintiles of night-time SBP (<bold>a</bold>), HbA<sub>1c</sub> (<bold>b</bold>) and eGFR (<bold>c</bold>)</p></caption><graphic xlink:href="125_2009_1577_Fig1_HTML" id="MO1"/></fig>The median uncorrected albumin concentration in morning spot urine tests in men was 4.2&#x000a0;mg/ml (interquartile range 2.0&#x02013;7.7, mean 6.11&#x02009;&#x000b1;&#x02009;10.26, geometric mean 4.2) and in women 3.2&#x000a0;mg/ml (interquartile range 1.5&#x02013;6.2, mean 5.04&#x02009;&#x000b1;&#x02009;5.27, geometric mean 3.6). The albumin/creatinine ratio is higher in women, as expected, because of the higher UACR exclusion values for female patients (&#x02265;3.96 mg/mmol) than for men (&#x02265;2.83&#x000a0;mg/mmol); however the absolute uncorrected albumin concentration is lower in women as a result of markedly lower urinary creatinine concentrations in women.</p><p><bold>Ambulatory BP (Holter monitoring) in a sub-cohort of patients</bold> The values of 24&#x000a0;h ABPM prior to taking the study medication were available in a sub-cohort of 1,234 of the 4,449 patients (567 men, 667 women). The values of different ABPM variables are given in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. The average BP was 139.6/81.5&#x000a0;mmHg, confirming the results obtained in the office BP cohort.
<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Twenty-four hour data from ABPM</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reading</th><th>Value (<italic>n</italic>&#x02009;=&#x02009;1,234)</th></tr></thead><tbody><tr><td>24&#x000a0;h SBP</td><td char="&#x000b1;" align="char">139.6&#x02009;&#x000b1;&#x02009;15.4 (138.9)</td></tr><tr><td>24&#x000a0;h DBP</td><td char="&#x000b1;" align="char">81.5&#x02009;&#x000b1;&#x02009;8.1 (81.1)</td></tr><tr><td>Daytime SBP</td><td char="&#x000b1;" align="char">143.6&#x02009;&#x000b1;&#x02009;15.6 (143.4)</td></tr><tr><td>Daytime DBP</td><td char="&#x000b1;" align="char">84.3&#x02009;&#x000b1;&#x02009;8.5 (83.8)</td></tr><tr><td>Night-time SBP</td><td char="&#x000b1;" align="char">133.8&#x02009;&#x000b1;&#x02009;17.9 (131.7)</td></tr><tr><td>Night-time DBP</td><td char="&#x000b1;" align="char">77.4&#x02009;&#x000b1;&#x02009;9.4 (6.9)</td></tr><tr><td>24&#x000a0;h pulse pressure</td><td char="&#x000b1;" align="char">58.1&#x02009;&#x000b1;&#x02009;10.3 (57.6)</td></tr><tr><td>Daytime pulse pressure</td><td char="&#x000b1;" align="char">59.3&#x02009;&#x000b1;&#x02009;10.7 (59.0)</td></tr><tr><td>Night-time pulse pressure</td><td char="&#x000b1;" align="char">56.5&#x02009;&#x000b1;&#x02009;11.7 (55.1)</td></tr><tr><td>Mean daytime SBP minus mean night-time SBP</td><td char="&#x000b1;" align="char">9.7&#x02009;&#x000b1;&#x02009;12.1 (10.0)</td></tr><tr><td>Mean daytime DBP minus mean night-time DBP</td><td char="&#x000b1;" align="char">6.9&#x02009;&#x000b1;&#x02009;7.3 (6.9)</td></tr></tbody></table><table-wrap-foot><p>Values are means &#x000b1; SD (median)</p></table-wrap-foot></table-wrap></p><p><bold>Correlation of albuminuria with continuous variables</bold> The correlations for different continuous variables were calculated. We found a correlation with several commonly measured variables. The strongest correlation was observed for night-time SBP and HbA<sub>1c</sub> levels (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> and Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a, b</xref>). eGFR was correlated as well, but the correlation was moderate (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>). Multivariate analysis in the total cohort and in the sub-cohort of patients with ABPM confirmed that HbA<sub>1c</sub> and SBP had the best correlation with UACR (Tables&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> and <xref rid="Tab5" ref-type="table">5</xref>).
<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Spearman rank correlation coefficients (<italic>r</italic><sub>s</sub>) by univariate analysis with UACR (morning spot urine) as the dependent variable</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th><italic>r</italic><sub>s</sub></th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>Night-time SBP<sup>a</sup></td><td char="." align="char">0.19</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>HbA<sub>1c</sub></td><td char="." align="char">0.18</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>Mean 24&#x000a0;h SBP<sup>a</sup></td><td char="." align="char">0.16</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>Fasting glucose</td><td char="." align="char">0.16</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>Night-time DBP<sup>a</sup></td><td char="." align="char">0.12</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>Mean 24&#x000a0;h DBP*</td><td char="." align="char">0.11</td><td char="." align="char">0.0001</td></tr><tr><td>Office SBP (sitting)</td><td char="." align="char">0.11</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>Office SBP (standing)</td><td char="." align="char">0.10</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>eGFR</td><td char="." align="char">0.10</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>Haemoglobin</td><td char="." align="char">&#x02212;0.10</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>Triacylglycerols</td><td char="." align="char">0.09</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>Office pulse pressure (amplitude)</td><td char="." align="char">0.08</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>Uric acid</td><td char="." align="char">&#x02212;0.08</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>Duration of diabetes</td><td char="." align="char">0.07</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>Office DBP (standing)</td><td char="." align="char">0.07</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>Office DBP (sitting)</td><td char="." align="char">0.06</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>BMI</td><td char="." align="char">0.06</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>Total cholesterol</td><td char="." align="char">0.05</td><td char="." align="char">0.0014</td></tr></tbody></table><table-wrap-foot><p>No univariate Spearman correlation to: ABPM SBP variability (maximum&#x02212;minimum during 24&#x000a0;h period), LDL-cholesterol, HDL-cholesterol or neutrophil counts</p><p><sup>a</sup>ABPM (Holter monitoring) data in sub-cohort of 1,234 patients</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Multivariate regression model with stepwise selection of log<sub><italic>e</italic></sub> UACR</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Order</th><th>Variable</th><th>Partial <italic>R</italic><sup>2</sup></th><th><italic>p</italic> value</th><th>Regression coefficient<sup>a</sup></th></tr></thead><tbody><tr><td>1</td><td>HbA<sub>1c</sub></td><td char="." align="char">0.0344</td><td char="." align="char">&#x0003c;0.0001</td><td char="." align="char">0.05419</td></tr><tr><td>2</td><td>Sex (females higher) (coded 0=male, 1=female)</td><td char="." align="char">0.0137</td><td char="." align="char">&#x0003c;0.0001</td><td char="." align="char">0.16693</td></tr><tr><td>3</td><td>Office SBP (sitting)</td><td char="." align="char">0.0126</td><td char="." align="char">&#x0003c;0.0001</td><td char="." align="char">0.00422</td></tr><tr><td>4</td><td>eGFR</td><td char="." align="char">0.0123</td><td char="." align="char">&#x0003c;0.0001</td><td char="." align="char">0.00574</td></tr><tr><td>5</td><td>Triacylglycerols</td><td char="." align="char">0.0047</td><td char="." align="char">&#x0003c;0.0001</td><td char="." align="char">0.03430</td></tr><tr><td>6</td><td>Haemoglobin</td><td char="." align="char">0.0034</td><td char="." align="char">&#x0003c;0.0001</td><td char="." align="char">&#x02212;0.00420</td></tr><tr><td>7</td><td>Family history of diabetes</td><td char="." align="char">0.0028</td><td char="." align="char">0.0002</td><td char="." align="char">&#x02212;0.06626</td></tr><tr><td>8</td><td>Age</td><td char="." align="char">0.0023</td><td char="." align="char">0.0010</td><td char="." align="char">0.00533</td></tr><tr><td>9</td><td>Heart rate (sitting)</td><td char="." align="char">0.0020</td><td char="." align="char">0.0021</td><td char="." align="char">0.00313</td></tr><tr><td>10</td><td>Antihypertensive treatment</td><td char="." align="char">0.0021</td><td char="." align="char">0.0015</td><td char="." align="char">0.08129</td></tr><tr><td>11</td><td>Smoking status (ordinally coded 0=non-smoker, 1=ex-smoker, 2=smoker)</td><td char="." align="char">0.0019</td><td char="." align="char">0.0027</td><td char="." align="char">0.04451</td></tr><tr><td>12</td><td>Fasting glucose</td><td char="." align="char">0.0009</td><td char="." align="char">0.0326</td><td char="." align="char">0.01034</td></tr><tr><td>13</td><td>HDL-cholesterol</td><td char="." align="char">0.0009</td><td char="." align="char">0.0409</td><td char="." align="char">&#x02212;0.07907</td></tr><tr><td>14</td><td>Family history of CVD</td><td char="." align="char">0.0008</td><td char="." align="char">0.0436</td><td char="." align="char">&#x02212;0.04354</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Variables with a positive sign for the regression coefficient, increasing albuminuria; with a negative sign, decreasing albuminuria</p><p>CVD, cardiovascular disease</p></table-wrap-foot></table-wrap><table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>Multivariate regression model with stepwise selection of log<sub><italic>e</italic></sub> UACR in the sub-cohort with ABPM (<italic>n</italic>&#x02009;=&#x02009;1,234)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Order</th><th>Variable</th><th>Partial <italic>R</italic><sup>2</sup></th><th><italic>p</italic> value</th><th>Regression coefficient</th></tr></thead><tbody><tr><td>1</td><td>HbA<sub>1c</sub></td><td char="." align="char">0.0484</td><td char="." align="char">&#x0003c;0.0001</td><td char="." align="char">0.08013</td></tr><tr><td>2</td><td>ABPM night-time SBP</td><td char="." align="char">0.0267</td><td char="." align="char">&#x0003c;0.0001</td><td char="." align="char">0.00405</td></tr><tr><td>3</td><td>Office SBP (sitting)</td><td char="." align="char">0.0103</td><td char="." align="char">0.0002</td><td char="." align="char">0.00484</td></tr><tr><td>4</td><td>Family history of diabetes</td><td char="." align="char">0.0094</td><td char="." align="char">0.0004</td><td char="." align="char">&#x02212;0.14284</td></tr><tr><td>5</td><td>Antihypertensive treatment</td><td char="." align="char">0.0062</td><td char="." align="char">0.0037</td><td char="." align="char">0.14548</td></tr><tr><td>6</td><td>eGFR</td><td char="." align="char">0.0061</td><td char="." align="char">0.0039</td><td char="." align="char">0.00405</td></tr><tr><td>7</td><td>Sex (females higher) (coded 0=male, 1=female)</td><td char="." align="char">0.0047</td><td char="." align="char">0.0113</td><td char="." align="char">0.11502</td></tr><tr><td>8</td><td>Duration of type 2 diabetes</td><td char="." align="char">0.0042</td><td char="." align="char">0.0159</td><td char="." align="char">0.00063</td></tr><tr><td>9</td><td>Standing minus sitting office DBP</td><td char="." align="char">0.0031</td><td char="." align="char">0.0397</td><td char="." align="char">0.00768</td></tr><tr><td>10</td><td>Standing minus sitting office heart rate</td><td char="." align="char">0.0031</td><td char="." align="char">0.0372</td><td char="." align="char">&#x02212;0.00815</td></tr></tbody></table></table-wrap></p><p><bold>Correlation of albuminuria with categorical variables</bold> The correlations for a set of categorical variables were calculated. A highly significant correlation existed between the degree of UACR and variables of the metabolic syndrome, BP and female sex (Table&#x000a0;<xref rid="Tab6" ref-type="table">6</xref>).
<table-wrap id="Tab6"><label>Table&#x000a0;6</label><caption><p>Correlation of UACR with categorical variables</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Effect on albuminuria</th><th><italic>p</italic> value<sup>a</sup></th></tr></thead><tbody><tr><td>Increased waist circumference</td><td>Higher</td><td>&#x0003c;0.0001</td></tr><tr><td>&#x000a0;Men &#x0003e;102&#x000a0;cm</td><td>Higher</td><td>0.0171</td></tr><tr><td>&#x000a0;Women &#x0003e;88&#x000a0;cm</td><td>Higher</td><td>NS</td></tr><tr><td>Metabolic syndrome (yes) (NCEP-ATP-III)</td><td>Higher</td><td>&#x0003c;0.0001</td></tr><tr><td>Female sex</td><td>Higher</td><td>&#x0003c;0.0001</td></tr><tr><td>Family history of diabetes</td><td>Lower</td><td>0.0068</td></tr><tr><td>Family history of CVD</td><td>Lower</td><td>0.0252</td></tr><tr><td>Antihypertensive medication</td><td>Higher</td><td>&#x0003c;0.0001</td></tr><tr><td>Amlodipine treatment</td><td>Higher</td><td>&#x0003c;0.0001</td></tr><tr><td>Insulin treatment</td><td>Higher</td><td>0.0280</td></tr><tr><td>Office SBP &#x0003e;140&#x000a0;mmHg or DBP &#x0003e;90&#x000a0;mmHg</td><td>Higher</td><td>&#x0003c;0.0001</td></tr><tr><td>Office SBP &#x0003e;130&#x000a0;mmHg or DBP &#x0003e;85&#x000a0;mmHg</td><td>Higher</td><td>&#x0003c;0.0001</td></tr><tr><td>Smoking: male ex-smokers vs non-smokers and smokers</td><td>Higher</td><td>0.0002</td></tr></tbody></table><table-wrap-foot><p>Categorical factors that were not significant included: family history of renal disease, family history of hypertension, current use of aspirin or statins, ethnic origin, smoking in women</p><p><sup>a</sup>Two-sided Wilcoxon rank sum test; normal approximation of test statistics</p><p>CVD, cardiovascular disease</p></table-wrap-foot></table-wrap></p><p><bold>Night-time BP as determinant of albuminuria</bold> As the night-time BP showed a high correlation in the uni- and multivariate analysis (ABPM sub-cohort), the effect of BP changes from day to night were analysed. The mean UACR was 0.63&#x02009;&#x000b1;&#x02009;0.53&#x000a0;mg/mmol in patients with an increased BP during the night and 0.54&#x02009;&#x000b1;&#x02009;0.44&#x000a0;mg/mmol in patients with an inverted BP profile (i.e. increased BP during the day; Table&#x000a0;<xref rid="Tab7" ref-type="table">7</xref>).
<table-wrap id="Tab7"><label>Table&#x000a0;7</label><caption><p>UACR (mg/mmol) in patients (ABPM sub-cohort) with night-time SBP lower or higher than daytime SBP</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Data</th><th>SBP at night &#x02264;SBP in day (<italic>n</italic>&#x02009;=&#x02009;1,001)</th><th>SBP at night &#x02265;SBP in day (<italic>n</italic>&#x02009;=&#x02009;229)</th><th>Total (<italic>n</italic>&#x02009;=&#x02009;1,230)</th></tr></thead><tbody><tr><td>Mean&#x000b1;SD</td><td>0.54&#x02009;&#x000b1;&#x02009;0.44</td><td>0.63&#x02009;&#x000b1;&#x02009;0.53<sup>a</sup></td><td>0.55&#x02009;&#x000b1;&#x02009;0.46</td></tr><tr><td>Q1/median/Q3</td><td>0.26/0.37/0.68</td><td>0.31/0.45/0.82</td><td>0.27/0.42/0.68</td></tr><tr><td>Minimum to maximum</td><td>0.11&#x02013;3.42</td><td>0.11&#x02013;4.03</td><td>0.11&#x02013;4.03</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup><italic>p</italic>&#x02009;=&#x02009;0.0076 vs SBP at night &#x02264;SBP in day</p><p>Q, quartile</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4"><title>Discussion</title><p>This large study comprised 4,449 relatively young type 2 diabetic patients (mean age 57.7&#x000a0;years, range 28&#x02013;75) with an average duration of diabetes of 6.1&#x000a0;years. At baseline they had moderately controlled median BP (140/84&#x000a0;mmHg), but attenuated lowering of night-time SBP (&#x02212;6.8%). The median HbA<sub>1c</sub> was relatively low (7.3%), but the cardiovascular risk factor profile was high (67.0% had &#x02265;4 cardiovascular risk factors).</p><p>As evaluated by Spearman correlation coefficient analysis, the factors most strongly correlated with the variation in albuminuria within the normoalbuminuric range comprised BP variables, most strongly, night-time SBP and further BP indices: mean 24&#x000a0;h SBP, night-time SBP, office SBP in men (but not in women), mean 24&#x000a0;h DBP and office DBP as well as pulse pressure as an index of vascular stiffness [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>The BP data are in good agreement with previous reports in smaller cohorts reported in the literature. In type 1 diabetes, higher night-time SBP predicted the onset of microalbuminuria [<xref ref-type="bibr" rid="CR20">20</xref>] and the occurrence of cardiovascular events [<xref ref-type="bibr" rid="CR21">21</xref>], respectively. Similarly in type 2 diabetes, attenuated dipping and elevated night-time BP are frequent [<xref ref-type="bibr" rid="CR22">22</xref>]. Night-time SBP was higher than daytime SBP in adult diabetic patients who developed microalbuminuria [<xref ref-type="bibr" rid="CR22">22</xref>]. Attenuated dipping was also found to be correlated with coronary events [<xref ref-type="bibr" rid="CR23">23</xref>]. In one relatively small recent study, however, the correlation of albuminuria to night-time BP dipping was less tight than to absolute BP [<xref ref-type="bibr" rid="CR24">24</xref>]. Furthermore, masked hypertension is also correlated with albuminuria [<xref ref-type="bibr" rid="CR25">25</xref>]. In the present study, the ABPM sub-cohort with higher night-time than daytime BP had significantly higher (<italic>p</italic>&#x02009;=&#x02009;0.0076 by Wilcoxon rank sum test) albumin excretion compared with patients with lower night-time than daytime BP.</p><p>In a very small sample of patients with type 2 diabetes, a recent report found that pulse pressure (as a potential indicator of vascular stiffness) was related to albumin excretion [<xref ref-type="bibr" rid="CR26">26</xref>]. This finding is confirmed in our much larger cohort. The present study, in normoalbuminuric type 2 diabetic patients, extends the findings on pulse pressure in the large cross-sectional study in microalbuminuric and proteinuric type 2 diabetic patients by Tanaka et al. [<xref ref-type="bibr" rid="CR27">27</xref>]: the present study documents that a relationship between pulse pressure and albuminuria is found even in normoalbuminuric type 2 diabetic patients. Tanaka et al. had also noted a correlation with aortic pulse wave velocity and carotid intima&#x02013;media thickness. In a small sample of normo- and microalbuminuric type 2 diabetic patients, albuminuria was correlated with markers of endothelial cell dysfunction [<xref ref-type="bibr" rid="CR28">28</xref>], and this may explain, at least in part, this correlation to pulse wave velocity.</p><p>In the present study albuminuria was also significantly correlated with indices of glycaemic control, i.e. HbA<sub>1c</sub>, fasting glucose and duration of diabetes, as well as insulin treatment as a categorical variable. Individuals requiring insulin treatment and individuals with longer duration of diabetes presumably have more advanced renal lesions.</p><p>Furthermore, BMI and the categorical variables of elevated waist circumference and the metabolic syndrome according to NCEP-ATP-III criteria [<xref ref-type="bibr" rid="CR29">29</xref>] were correlated with albuminuria as well. This observation is again in line with previous communications and the observation that UAE reflects insulin resistance [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p>In the general non-diabetic population [<xref ref-type="bibr" rid="CR31">31</xref>] and in essential hypertension [<xref ref-type="bibr" rid="CR32">32</xref>] impaired glucose tolerance increases the risk of microalbuminuria. Even sub-diabetic glycaemia increased the risk of microalbuminuria in the &#x02018;Framingham Offspring&#x02019; study [<xref ref-type="bibr" rid="CR33">33</xref>]. In the UKPDS study, the patients who presented with type 2 diabetes and had lower glycaemia had also a lower risk of albuminuria [<xref ref-type="bibr" rid="CR34">34</xref>]. In the Australian Diabetes, Obesity and Lifestyle Study [<xref ref-type="bibr" rid="CR35">35</xref>], the prevalence of albuminuria increased significantly with increasing glycaemia. It is particularly postprandial glycaemia, not measured in the present study, which is best correlated with albuminuria [<xref ref-type="bibr" rid="CR36">36</xref>], so that the overall impact of glycaemia may even have been somewhat underestimated in the present study.</p><p>In the general population the metabolic syndrome is associated with both microalbuminuria and chronic kidney disease [<xref ref-type="bibr" rid="CR37">37</xref>] and the same is observed in hypertensive patients [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p>In the general non-diabetic population, waist circumference, an index of visceral obesity, also predicted higher albumin excretion [<xref ref-type="bibr" rid="CR38">38</xref>]. In type 1 [<xref ref-type="bibr" rid="CR39">39</xref>] and type 2 diabetes as well [<xref ref-type="bibr" rid="CR40">40</xref>], waist circumference had been found to be a predictor of microalbuminuria.</p><p>In the above study a positive relationship was found between albuminuria and estimated GFR [<xref ref-type="bibr" rid="CR41">41</xref>], indicating that hyperfiltration presumably plays a role in the pathogenesis of high normal albuminuria in type 2 diabetes. A note of caution is appropriate, however, since in diabetic patients eGFR is not a reliable indicator of true GFR, at least in individual patients [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p>In agreement with reports in the literature on patients with type 1 [<xref ref-type="bibr" rid="CR43">43</xref>] and type 2 diabetes [<xref ref-type="bibr" rid="CR44">44</xref>], albuminuria was also correlated, although not markedly, to triacylglycerol, total cholesterol and LDL-cholesterol.</p><p>A recent report found a positive correlation between uric acid and albuminuria in male type 2 diabetic patients [<xref ref-type="bibr" rid="CR45">45</xref>] in whom confounding factors had been excluded, such as use of allopurinol, diuretics or alcohol consumption. In the present ROADMAP Study the correlation was negative and this persisted even when adjusted for the potential confounding effect of alcohol use.</p><p>The use of and presumably need for antihypertensive medication, particularly amlodipine, was positively related to albuminuria. The correlation with antihypertensive medication may be an example of confounding by indication, i.e. that patients with more severe and more advanced disease required antihypertensive medication and had also higher rates of albuminuria. The significant effect of amlodipine, however, may be more complex. At the time of screening the patients had not yet received, or were off, renin&#x02013;angiotensin receptor blockers for at least 6&#x000a0;months.</p><p>The strength of our study is that we analysed UACR in a large sample of type 2 diabetic patients without kidney disease (no microalbuminuria, eGFR&#x02009;&#x0003e;&#x02009;60&#x000a0;ml&#x000a0;min<sup>&#x02212;1</sup> 1.73&#x000a0;m<sup>&#x02212;2</sup>). As the inclusion and exclusion criteria were fulfilled by the majority of the screened patients, this study population is representative of the majority of type 2 diabetic patients. Moreover, our data on UACR are based on the measurement of albuminuria in three morning spot urines.</p><p>It should be noted that only 10% of the total variance of the UACR could be explained by the degree of blood glucose control, BP variables, lipids and age. Verhave et al. analysed the correlation of albumin excretion (UAE) with cardiovascular risk factors in 7,841 patients of the PREVEND cohort [<xref ref-type="bibr" rid="CR45">45</xref>]. In their cohort, taken from the general population, only 3.5% had diabetes and 14% microalbuminuria at baseline. They found a correlation between UAE and male sex, age, SBP, DBP, fasting glucose levels, BMI, smoking and creatinine clearance. In a multivariate analysis only 22% of the variance of UAE could be explained by these variables. In the PREVEND cohort the strongest correlation existed between glucose level and UAE. Since all patients in the ROADMAP Study had diabetes, this observation might explain why we were only able to explain 10% of the variance of the log<sub><italic>e</italic></sub> UACR. The relatively modest correlation may also be because of the fact that most of the patients were in the low normoalbuminuric range at baseline. In this low range the variability is known to be relatively high. The intra-individual variability of the three repeated UACR measurements was 55% in the ROADMAP cohort.</p><p>Therefore, the correlation observed points more to the direction (thus providing a potential target of treatment) rather than reflecting the magnitude of the relationship. The identified variables correlate not only with the degree of albuminuria within the normoalbuminuric range but might also be predictors for the development of microalbuminuria (Table&#x000a0;<xref rid="Tab8" ref-type="table">8</xref>).
<table-wrap id="Tab8"><label>Table&#x000a0;8</label><caption><p>Determinants of baseline values for the development of microalbuminuria</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Value</th><th colspan="3">Study</th></tr><tr><th>Direct [<xref ref-type="bibr" rid="CR49">49</xref>]<sup>a</sup></th><th>Hope [<xref ref-type="bibr" rid="CR50">50</xref>]<sup>b</sup></th><th>Benedict [<xref ref-type="bibr" rid="CR17">17</xref>]<sup>c</sup></th></tr></thead><tbody><tr><td>Age</td><td>n.d.</td><td>+</td><td>n.d.</td></tr><tr><td>Male sex</td><td>+</td><td>+</td><td>n.d.</td></tr><tr><td>SBP</td><td>n.d.</td><td>+</td><td>=</td></tr><tr><td>DBP</td><td>n.d.</td><td>=</td><td>=</td></tr><tr><td>Pulse pressure</td><td>n.d.</td><td>n.d.</td><td>=</td></tr><tr><td>BMI kg/m<sup>2</sup></td><td>n.d.</td><td>+</td><td>n.d.</td></tr><tr><td>Cholesterol</td><td>n.d.</td><td>=</td><td>n.d.</td></tr><tr><td>Low HDL-cholesterol</td><td>n.d.</td><td>=</td><td>n.d.</td></tr><tr><td>Smoking</td><td>n.d.</td><td>+</td><td>n.d.</td></tr><tr><td>Baseline UAE</td><td>+</td><td>n.d.</td><td>n.d.</td></tr><tr><td>Retinopathy</td><td>+</td><td>n.d.</td><td>n.d.</td></tr><tr><td>HbA<sub>1c</sub></td><td>+</td><td>n.d.</td><td>n.d.</td></tr></tbody></table><table-wrap-foot><p>n.d., not determined; +, positive correlation; =, no significant correlation</p><p><sup>a</sup>The Diabetes Incidence after REnal Transplantation (DIRECT) Study: 3,326 and with type 1 and 1,905 type 2 diabetes were followed for 4.7&#x000a0;years</p><p><sup>b</sup>The Heart Outcomes Prevention Evaluation (HOPE) Study: 9,043 patients with and without type 2 diabetes were followed for 4.5&#x000a0;years and determinants of albuminuria assessed</p><p><sup>c</sup>The Bergamo NEphrologic Diabetes Complications Trial (BENEDICT): 1,204 patients with type 2 diabetes were followed for 3.6&#x000a0;years and risk factors for the development of microalbuminuria analysed</p></table-wrap-foot></table-wrap></p><p>Studies in normoalbuminuric diabetic patients have additional limitations. First, on the one hand in diabetic patients albuminuria is certainly correlated with the severity of glomerular lesions [<xref ref-type="bibr" rid="CR46">46</xref>], but the correlation is not strict, particularly in type 2 diabetes [<xref ref-type="bibr" rid="CR47">47</xref>]. Albuminuria therefore does not permit conclusions with respect to diabetic glomerular lesions. On the other hand, diabetic glomerular lesions may even precede the onset of albuminuria [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>Second, microalbuminuria is present in 16% of patients at the time of diagnosis of type 2 diabetes [<xref ref-type="bibr" rid="CR47">47</xref>]. Microalbuminuria frequently precedes the onset of overt type 2 diabetes [<xref ref-type="bibr" rid="CR35">35</xref>] and one potential explanation may be the relatively strong correlation between albuminuria and the metabolic syndrome, a prediabetic state with insulin resistance [<xref ref-type="bibr" rid="CR48">48</xref>].</p><p>In conclusion, the present baseline data of the ROADMAP Study suggest that albuminuria is a continuous variable, and that even in normoalbuminuric type 2 diabetic patients albumin excretion rates are correlated with a number of factors which are potentially susceptible to therapeutic intervention, although certainly correlation does not necessarily imply causality.</p></sec></body><back><ack><title>Acknowledgements</title><p>This study was sponsored by Daichii-Sankyo. The statistical support of L. Pecen (Institute of Computer Science Czech Academy of Sciences, Prague, Czech Republic) is gratefully acknowledged.</p><p><bold>Duality of interest</bold> All authors have received honoraria from Daichii-Sankyo.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambers Heerspink</surname><given-names>HJ</given-names></name><name><surname>Brinkman</surname><given-names>JW</given-names></name><name><surname>Bakker</surname><given-names>SJ</given-names></name><name><surname>Gansevoort</surname><given-names>RT</given-names></name><name><surname>Zeeuw</surname><given-names>D</given-names></name></person-group><article-title>Update on microalbuminuria as a biomarker in renal and cardiovascular disease</article-title><source>Curr Opin Nephrol Hypertens</source><year>2006</year><volume>15</volume><fpage>631</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1097/01.mnh.0000247496.54882.3f</pub-id><pub-id pub-id-type="pmid">17053479</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Senator</surname><given-names>H</given-names></name></person-group><source>Albuminuria in health and disease</source><year>1884</year><publisher-loc>London</publisher-loc><publisher-name>The New Sydenham Society</publisher-name></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mogensen</surname><given-names>CE</given-names></name></person-group><article-title>Urinary albumin excretion in diabetes</article-title><source>Lancet</source><year>1971</year><volume>2</volume><fpage>601</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">4106122</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mogensen</surname><given-names>C</given-names></name></person-group><article-title>Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes</article-title><source>N Engl J Med</source><year>1984</year><volume>310</volume><fpage>356</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">6690964</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viberti</surname><given-names>GC</given-names></name><name><surname>Hill</surname><given-names>RD</given-names></name><name><surname>Jarrett</surname><given-names>RJ</given-names></name><name><surname>Argyropoulos</surname><given-names>A</given-names></name><name><surname>Mahmud</surname><given-names>U</given-names></name><name><surname>Keen</surname><given-names>H</given-names></name></person-group><article-title>Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus</article-title><source>Lancet</source><year>1982</year><volume>1</volume><fpage>1430</fpage><lpage>1432</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(82)92450-3</pub-id><pub-id pub-id-type="pmid">6123720</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wachtell</surname><given-names>K</given-names></name><name><surname>Ibsen</surname><given-names>H</given-names></name><name><surname>Olsen</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study</article-title><source>Ann Intern Med</source><year>2003</year><volume>139</volume><fpage>901</fpage><lpage>906</lpage><pub-id pub-id-type="pmid">14644892</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rachmani</surname><given-names>R</given-names></name><name><surname>Levi</surname><given-names>Z</given-names></name><name><surname>Lidar</surname><given-names>M</given-names></name><name><surname>Slavachevski</surname><given-names>I</given-names></name><name><surname>Half-Onn</surname><given-names>E</given-names></name><name><surname>Ravid</surname><given-names>M</given-names></name></person-group><article-title>Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: lessons from an 8-year follow-up study of 599 patients</article-title><source>Diabetes Res Clin Pract</source><year>2000</year><volume>49</volume><fpage>187</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/S0168-8227(00)00155-8</pub-id><pub-id pub-id-type="pmid">10963831</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnlov</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>JC</given-names></name><name><surname>Meigs</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study</article-title><source>Circulation</source><year>2005</year><volume>112</volume><fpage>969</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.538132</pub-id><pub-id pub-id-type="pmid">16087792</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruggenenti</surname><given-names>P</given-names></name><name><surname>Remuzzi</surname><given-names>G</given-names></name></person-group><article-title>Time to abandon microalbuminuria?</article-title><source>Kidney Int</source><year>2006</year><volume>70</volume><fpage>1214</fpage><lpage>1222</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5001729</pub-id><pub-id pub-id-type="pmid">16871239</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallego</surname><given-names>PH</given-names></name><name><surname>Gilbey</surname><given-names>AJ</given-names></name><name><surname>Grant</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Early changes in 24-hour ambulatory blood pressure are associated with high normal albumin excretion rate in children with type 1 diabetes mellitus</article-title><source>J Pediatr Endocrinol Metab</source><year>2005</year><volume>18</volume><fpage>879</fpage><lpage>885</lpage><pub-id pub-id-type="pmid">16279366</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrin</surname><given-names>NE</given-names></name><name><surname>Torbjornsdotter</surname><given-names>TB</given-names></name><name><surname>Jaremko</surname><given-names>GA</given-names></name><name><surname>Berg</surname><given-names>UB</given-names></name></person-group><article-title>Follow-up of kidney biopsies in normoalbuminuric patients with type 1 diabetes</article-title><source>Pediatr Nephrol</source><year>2004</year><volume>19</volume><fpage>1004</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1007/s00467-004-1509-x</pub-id><pub-id pub-id-type="pmid">15221426</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>ML</given-names></name><name><surname>Craig</surname><given-names>ME</given-names></name><name><surname>Chan</surname><given-names>AK</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Verge</surname><given-names>CF</given-names></name><name><surname>Donaghue</surname><given-names>KC</given-names></name></person-group><article-title>Natural history and risk factors for microalbuminuria in adolescents with type 1 diabetes: a longitudinal study</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>2072</fpage><lpage>2077</lpage><pub-id pub-id-type="doi">10.2337/dc06-0239</pub-id><pub-id pub-id-type="pmid">16936155</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giorgino</surname><given-names>F</given-names></name><name><surname>Laviola</surname><given-names>L</given-names></name><name><surname>Cavallo Perin</surname><given-names>P</given-names></name><name><surname>Solnica</surname><given-names>B</given-names></name><name><surname>Fuller</surname><given-names>J</given-names></name><name><surname>Chaturvedi</surname><given-names>N</given-names></name></person-group><article-title>Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: the EURODIAB Prospective Complications Study</article-title><source>Diabetologia</source><year>2004</year><volume>47</volume><fpage>1020</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1007/s00125-004-1413-8</pub-id><pub-id pub-id-type="pmid">15170497</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hovind</surname><given-names>P</given-names></name><name><surname>Tarnow</surname><given-names>L</given-names></name><name><surname>Rossing</surname><given-names>P</given-names></name><etal/></person-group><article-title>Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study</article-title><source>BMJ</source><year>2004</year><volume>328</volume><fpage>1105</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1136/bmj.38070.450891.FE</pub-id><pub-id pub-id-type="pmid">15096438</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Komatsu</surname><given-names>M</given-names></name><name><surname>Komiya</surname><given-names>I</given-names></name><etal/></person-group><article-title>Development, progression, and regression of microalbuminuria in Japanese patients with type 2 diabetes under tight glycemic and blood pressure control: the Kashiwa Study</article-title><source>Diabetes Care</source><year>2005</year><volume>28</volume><fpage>2733</fpage><lpage>2738</lpage><pub-id pub-id-type="doi">10.2337/diacare.28.11.2733</pub-id><pub-id pub-id-type="pmid">16249548</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haller</surname><given-names>H</given-names></name><name><surname>Viberti</surname><given-names>GC</given-names></name><name><surname>Mimran</surname><given-names>A</given-names></name><etal/></person-group><article-title>Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Study</article-title><source>J Hypertens</source><year>2006</year><volume>24</volume><fpage>403</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1097/01.hjh.0000202820.56201.e6</pub-id><pub-id pub-id-type="pmid">16508590</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruggenenti</surname><given-names>P</given-names></name><name><surname>Fassi</surname><given-names>A</given-names></name><name><surname>Ilieva</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Preventing microalbuminuria in type 2 diabetes</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>1941</fpage><lpage>1951</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa042167</pub-id><pub-id pub-id-type="pmid">15516697</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Strippoli GF, Craig M, Navaneethan SD, Craig JC (2006) Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006, CD006257</mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strain</surname><given-names>WD</given-names></name><name><surname>Chaturvedi</surname><given-names>N</given-names></name><name><surname>Dockery</surname><given-names>F</given-names></name><etal/></person-group><article-title>Increased arterial stiffness in Europeans and African Caribbeans with type 2 diabetes cannot be accounted for by conventional cardiovascular risk factors</article-title><source>Am J Hypertens</source><year>2006</year><volume>19</volume><fpage>889</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1016/j.amjhyper.2006.01.009</pub-id><pub-id pub-id-type="pmid">16942929</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lurbe</surname><given-names>E</given-names></name><name><surname>Redon</surname><given-names>J</given-names></name><name><surname>Kesani</surname><given-names>A</given-names></name><etal/></person-group><article-title>Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><fpage>797</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa013410</pub-id><pub-id pub-id-type="pmid">12226150</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Astrup</surname><given-names>AS</given-names></name><name><surname>Tarnow</surname><given-names>L</given-names></name><name><surname>Rossing</surname><given-names>P</given-names></name><name><surname>Pietraszek</surname><given-names>L</given-names></name><name><surname>Riis Hansen</surname><given-names>P</given-names></name><name><surname>Parving</surname><given-names>HH</given-names></name></person-group><article-title>Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study</article-title><source>Kidney Int</source><year>2005</year><volume>68</volume><fpage>1250</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2005.00521.x</pub-id><pub-id pub-id-type="pmid">16105058</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afsar</surname><given-names>B</given-names></name><name><surname>Sezer</surname><given-names>S</given-names></name><name><surname>Elsurer</surname><given-names>R</given-names></name><name><surname>Ozdemir</surname><given-names>FN</given-names></name></person-group><article-title>Is HOMA index a predictor of nocturnal nondipping in hypertensives with newly diagnosed type 2 diabetes mellitus?</article-title><source>Blood Press Monit</source><year>2007</year><volume>12</volume><fpage>133</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1097/MBP.0b013e3280b08379</pub-id><pub-id pub-id-type="pmid">17496462</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamura</surname><given-names>K</given-names></name><name><surname>Tsurumi</surname><given-names>Y</given-names></name><name><surname>Sakai</surname><given-names>M</given-names></name><etal/></person-group><article-title>A possible relationship of nocturnal blood pressure variability with coronary artery disease in diabetic nephropathy</article-title><source>Clin Exp Hypertens</source><year>2007</year><volume>29</volume><fpage>31</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1080/10641960601096760</pub-id><pub-id pub-id-type="pmid">17190729</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakano</surname><given-names>S</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Furuya</surname><given-names>K</given-names></name><etal/></person-group><article-title>Ambulatory blood pressure level rather than dipper/nondipper status predicts vascular events in type 2 diabetic subjects</article-title><source>Hypertens Res</source><year>2004</year><volume>27</volume><fpage>647</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1291/hypres.27.647</pub-id><pub-id pub-id-type="pmid">15750258</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leitao</surname><given-names>CB</given-names></name><name><surname>Canani</surname><given-names>LH</given-names></name><name><surname>Kramer</surname><given-names>CK</given-names></name><name><surname>Boza</surname><given-names>JC</given-names></name><name><surname>Pinotti</surname><given-names>AF</given-names></name><name><surname>Gross</surname><given-names>JL</given-names></name></person-group><article-title>Masked hypertension, urinary albumin excretion rate, and echocardiographic parameters in putatively normotensive type 2 diabetic patients</article-title><source>Diabetes Care</source><year>2007</year><volume>30</volume><fpage>1255</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.2337/dc06-2131</pub-id><pub-id pub-id-type="pmid">17303786</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anan</surname><given-names>F</given-names></name><name><surname>Masaki</surname><given-names>T</given-names></name><name><surname>Umeno</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Correlations of urinary albumin excretion and atherosclerosis in Japanese type 2 diabetic patients</article-title><source>Diabetes Res Clin Pract</source><year>2007</year><volume>77</volume><fpage>414</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2007.01.009</pub-id><pub-id pub-id-type="pmid">17316867</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Babazono</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name><name><surname>Iwamoto</surname><given-names>Y</given-names></name></person-group><article-title>Pulse pressure and chronic kidney disease in patients with type 2 diabetes</article-title><source>Hypertens Res</source><year>2006</year><volume>29</volume><fpage>345</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1291/hypres.29.345</pub-id><pub-id pub-id-type="pmid">16832155</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knudsen</surname><given-names>ST</given-names></name><name><surname>Jeppesen</surname><given-names>P</given-names></name><name><surname>Frederiksen</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Endothelial dysfunction, ambulatory pulse pressure and albuminuria are associated in type 2 diabetic subjects</article-title><source>Diabet Med</source><year>2007</year><volume>24</volume><fpage>911</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1111/j.1464-5491.2007.02197.x</pub-id><pub-id pub-id-type="pmid">17559428</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) (2001). JAMA 285:2486&#x02013;2497</mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parvanova</surname><given-names>AI</given-names></name><name><surname>Trevisan</surname><given-names>R</given-names></name><name><surname>Iliev</surname><given-names>IP</given-names></name><etal/></person-group><article-title>Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion</article-title><source>Diabetes</source><year>2006</year><volume>55</volume><fpage>1456</fpage><lpage>1462</lpage><pub-id pub-id-type="doi">10.2337/db05-1484</pub-id><pub-id pub-id-type="pmid">16644705</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franciosi</surname><given-names>M</given-names></name><name><surname>Pellegrini</surname><given-names>F</given-names></name><name><surname>Sacco</surname><given-names>M</given-names></name><etal/></person-group><article-title>Identifying patients at risk for microalbuminuria via interaction of the components of the metabolic syndrome: a cross-sectional analytic study</article-title><source>Clin J Am Soc Nephrol</source><year>2007</year><volume>2</volume><fpage>984</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.2215/CJN.01190307</pub-id><pub-id pub-id-type="pmid">17702724</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascual</surname><given-names>JM</given-names></name><name><surname>Rodilla</surname><given-names>E</given-names></name><name><surname>Gonzalez</surname><given-names>C</given-names></name><name><surname>Perez-Hoyos</surname><given-names>S</given-names></name><name><surname>Redon</surname><given-names>J</given-names></name></person-group><article-title>Long-term impact of systolic blood pressure and glycemia on the development of microalbuminuria in essential hypertension</article-title><source>Hypertension</source><year>2005</year><volume>45</volume><fpage>1125</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000167151.52825.11</pub-id><pub-id pub-id-type="pmid">15897369</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meigs</surname><given-names>JB</given-names></name><name><surname>D&#x02019;Agostino</surname><given-names>RB</given-names><suffix>Sr</suffix></name><name><surname>Nathan</surname><given-names>DM</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name></person-group><article-title>Longitudinal association of glycemia and microalbuminuria: the Framingham Offspring Study</article-title><source>Diabetes Care</source><year>2002</year><volume>25</volume><fpage>977</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.2337/diacare.25.6.977</pub-id><pub-id pub-id-type="pmid">12032102</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colagiuri</surname><given-names>S</given-names></name><name><surname>Cull</surname><given-names>CA</given-names></name><name><surname>Holman</surname><given-names>RR</given-names></name></person-group><article-title>Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61</article-title><source>Diabetes Care</source><year>2002</year><volume>25</volume><fpage>1410</fpage><lpage>1417</lpage><pub-id pub-id-type="doi">10.2337/diacare.25.8.1410</pub-id><pub-id pub-id-type="pmid">12145243</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tapp</surname><given-names>RJ</given-names></name><name><surname>Shaw</surname><given-names>JE</given-names></name><name><surname>Zimmet</surname><given-names>PZ</given-names></name><etal/></person-group><article-title>Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab)</article-title><source>Am J Kidney Dis</source><year>2004</year><volume>44</volume><fpage>792</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1016/S0272-6386(04)01079-0</pub-id><pub-id pub-id-type="pmid">15492944</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XL</given-names></name><name><surname>Lu</surname><given-names>JM</given-names></name><name><surname>Pan</surname><given-names>CY</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>CL</given-names></name></person-group><article-title>A comparison of urinary albumin excretion rate and microalbuminuria in various glucose tolerance subjects</article-title><source>Diabet Med</source><year>2005</year><volume>22</volume><fpage>332</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1111/j.1464-5491.2004.01408.x</pub-id><pub-id pub-id-type="pmid">15717883</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Muntner</surname><given-names>P</given-names></name><name><surname>Hamm</surname><given-names>LL</given-names></name><etal/></person-group><article-title>The metabolic syndrome and chronic kidney disease in U.S. adults</article-title><source>Ann Intern Med</source><year>2004</year><volume>140</volume><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">14757614</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnet</surname><given-names>F</given-names></name><name><surname>Marre</surname><given-names>M</given-names></name><name><surname>Halimi</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study</article-title><source>J Hypertens</source><year>2006</year><volume>24</volume><fpage>1157</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1097/01.hjh.0000226206.03560.ac</pub-id><pub-id pub-id-type="pmid">16685216</pub-id></mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boer</surname><given-names>IH</given-names></name><name><surname>Sibley</surname><given-names>SD</given-names></name><name><surname>Kestenbaum</surname><given-names>B</given-names></name><etal/></person-group><article-title>Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study</article-title><source>J Am Soc Nephrol</source><year>2007</year><volume>18</volume><fpage>235</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1681/ASN.2006040394</pub-id><pub-id pub-id-type="pmid">17151331</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>CH</given-names></name></person-group><article-title>Waist-to-height ratio is independently and better associated with urinary albumin excretion rate than waist circumference or waist-to-hip ratio in Chinese adult type 2 diabetic women but not men</article-title><source>Diabetes Care</source><year>2005</year><volume>28</volume><fpage>2249</fpage><lpage>2251</lpage><pub-id pub-id-type="doi">10.2337/diacare.28.9.2249</pub-id><pub-id pub-id-type="pmid">16123501</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>LA</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Greene</surname><given-names>T</given-names></name><name><surname>Levey</surname><given-names>AS</given-names></name></person-group><article-title>Assessing kidney function&#x02014;measured and estimated glomerular filtration rate</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><fpage>2473</fpage><lpage>2483</lpage><pub-id pub-id-type="doi">10.1056/NEJMra054415</pub-id><pub-id pub-id-type="pmid">16760447</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossing</surname><given-names>P</given-names></name><name><surname>Rossing</surname><given-names>K</given-names></name><name><surname>Gaede</surname><given-names>P</given-names></name><name><surname>Pedersen</surname><given-names>O</given-names></name><name><surname>Parving</surname><given-names>HH</given-names></name></person-group><article-title>Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>1024</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.2337/dc05-2201</pub-id><pub-id pub-id-type="pmid">16644632</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>MC</given-names></name><name><surname>Rosengard-Barlund</surname><given-names>M</given-names></name><name><surname>Mills</surname><given-names>V</given-names></name><etal/></person-group><article-title>Serum lipids and the progression of nephropathy in type 1 diabetes</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>317</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.2337/diacare.29.02.06.dc05-0809</pub-id><pub-id pub-id-type="pmid">16443880</pub-id></mixed-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>CH</given-names></name></person-group><article-title>Lipid abnormalities associated with urinary albumin excretion rate in Taiwanese type 2 diabetic patients</article-title><source>Kidney Int</source><year>2005</year><volume>67</volume><fpage>1547</fpage><lpage>1553</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2005.00235.x</pub-id><pub-id pub-id-type="pmid">15780110</pub-id></mixed-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>CH</given-names></name></person-group><article-title>Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan</article-title><source>Kidney Int</source><year>2005</year><volume>68</volume><fpage>796</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2005.00459.x</pub-id><pub-id pub-id-type="pmid">16014058</pub-id></mixed-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drummond</surname><given-names>K</given-names></name><name><surname>Mauer</surname><given-names>M</given-names></name></person-group><article-title>The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><fpage>1580</fpage><lpage>1587</lpage><pub-id pub-id-type="doi">10.2337/diabetes.51.5.1580</pub-id><pub-id pub-id-type="pmid">11978659</pub-id></mixed-citation></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fioretto</surname><given-names>P</given-names></name><name><surname>Mauer</surname><given-names>M</given-names></name></person-group><article-title>Histopathology of diabetic nephropathy</article-title><source>Semin Nephrol</source><year>2007</year><volume>27</volume><fpage>195</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/j.semnephrol.2007.01.012</pub-id><pub-id pub-id-type="pmid">17418688</pub-id></mixed-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mykkanen</surname><given-names>L</given-names></name><name><surname>Zaccaro</surname><given-names>DJ</given-names></name><name><surname>Wagenknecht</surname><given-names>LE</given-names></name><name><surname>Robbins</surname><given-names>DC</given-names></name><name><surname>Gabriel</surname><given-names>M</given-names></name><name><surname>Haffner</surname><given-names>SM</given-names></name></person-group><article-title>Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study</article-title><source>Diabetes</source><year>1998</year><volume>47</volume><fpage>793</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.2337/diabetes.47.5.793</pub-id><pub-id pub-id-type="pmid">9588452</pub-id></mixed-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilous</surname><given-names>R</given-names></name><name><surname>Chaturvedi</surname><given-names>N</given-names></name><name><surname>Sjolie</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials</article-title><source>Ann Intern Med</source><year>2009</year><volume>151</volume><issue>11&#x02013;20</issue><fpage>W3</fpage><lpage>W4</lpage></mixed-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>JF</given-names></name><name><surname>Gerstein</surname><given-names>HC</given-names></name><name><surname>Yi</surname><given-names>QL</given-names></name><etal/></person-group><article-title>Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study</article-title><source>J Am Soc Nephrol</source><year>2003</year><volume>14</volume><fpage>641</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1097/01.ASN.0000051594.21922.99</pub-id><pub-id pub-id-type="pmid">12595499</pub-id></mixed-citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>ABPM</term><def><p>Ambulatory BP monitoring</p></def></def-item><def-item><term>ARB</term><def><p>Angiotensin receptor blocker</p></def></def-item><def-item><term>DBP</term><def><p>Diastolic BP</p></def></def-item><def-item><term>eGFR</term><def><p>Estimated GFR</p></def></def-item><def-item><term>ROADMAP</term><def><p>Randomised Olmesartan and Diabetes Microalbuminuria Prevention (Study)</p></def></def-item><def-item><term>SBP</term><def><p>Systolic BP</p></def></def-item><def-item><term>UACR</term><def><p>Urinary albumin/creatinine ratio</p></def></def-item><def-item><term>UAE</term><def><p>Urinary albumin excretion</p></def></def-item></def-list></glossary><fn-group><fn><p>An erratum to this article can be found at 
						<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00125-009-1623-1">http://dx.doi.org/10.1007/s00125-009-1623-1</ext-link></p></fn></fn-group></back></article>